Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue was affected mainly by lower Neuroscience revenue resulting from the market penetration of generic VYVANSE products in the United States. Operating profit increased due to cost savings from company-wide efficiency programs, lower research and development expenses, lower business restructuring costs, and the completion of amortization of intangible assets related to VYVANSE/ELVANSE, among other factors.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥4,505,720 million (YoY -1.7%) |
| Operating profit | ¥408,761 million (YoY +19.3%) |
| Ordinary income | ¥260,189 million (YoY +48.6%) |
| Profit attributable to owners of the parent | ¥191,762 million (YoY +77.7%) |
| Net income per share | ¥121.75 |
| Operating Margin | 9.1％ |
| Equity ratio | End of the current fiscal period 50.3％ / End of previous period 48.7％ |
| Total assets | ¥15,453,113 million |
| Net assets | ¥7,774,800 million |
| Cash flows from operating activities | ¥1,041,431 million |
| Cash flows from investing activities | ¥-369,141 million |
| Cash flows from financing activities | ¥-496,820 million |
| Cash and cash equivalents at end of period | ¥595,054 million |
| Full-year earnings forecast | Net Sales ¥4,640,000 million (YoY +3.0%) / Operating profit ¥420,000 million (YoY +2.7%) / Ordinary income ¥252,000 million (YoY -3.1%) / Net income ¥166,000 million (YoY -13.4%) |
| Annual Dividend Forecast | ¥200 per share → ¥204 per share（+2.0%） |
| Payout ratio | 164.3％ |
| Shareholder Return Policy | Progressive dividends, with the annual dividend per share increased or maintained each year. Share buybacks will be conducted where appropriate. No numerical targets have been specified for the dividend payout ratio, DOE or other measures. |
| Regional sales | 4,331 Hundreds of millions of yen (YoY +3.5%), 21,648 Hundreds of millions of yen (YoY -9.0%), 11,462 Hundreds of millions of yen (YoY +8.6%), 2,541 Hundreds of millions of yen (YoY +7.8%), 1,951 Hundreds of millions of yen (YoY +1.8%), 987 Hundreds of millions of yen (YoY -0.7%), 797 Hundreds of millions of yen (YoY +10.2%), 1,339 Hundreds of millions of yen (YoY +3.9%) |
| Depreciation and amortization | ¥721,127 million |
| Impairment loss | ¥145,716 million |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (conference call; attendees not specified in the main text) |
| Issued Shares at Period-End | 1,591,229,109 |
| Treasury Shares at Period-End | 11,392,279 |
| Factors Behind Changes in Business Performance | Revenue was affected mainly by lower Neuroscience revenue resulting from the market penetration of generic VYVANSE products in the United States. Operating profit increased due to cost savings from company-wide efficiency programs, lower research and development expenses, lower business restructuring costs, and the completion of amortization of intangible assets related to VYVANSE/ELVANSE, among other factors. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue was affected mainly by lower Neuroscience revenue resulting from the market penetration of generic VYVANSE products in the United States. Operating profit benefited from cost savings under company-wide efficiency programs, lower research and development expenses, lower business restructuring costs, and the completion of amortization of intangible assets related to VYVANSE/ELVANSE, among other factors.